157 related articles for article (PubMed ID: 20480258)
1. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
[TBL] [Abstract][Full Text] [Related]
2. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
3. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
[TBL] [Abstract][Full Text] [Related]
5. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
Kovacs K; Scheithauer BW; Lombardero M; McLendon RE; Syro LV; Uribe H; Ortiz LD; Penagos LC
Acta Neuropathol; 2008 Feb; 115(2):261-2. PubMed ID: 17926052
[No Abstract] [Full Text] [Related]
6. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
Wang Y; Li J; Tohti M; Hu Y; Wang S; Li W; Lu Z; Ma C
J Exp Clin Cancer Res; 2014 Jul; 33(1):56. PubMed ID: 25027022
[TBL] [Abstract][Full Text] [Related]
7. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
[TBL] [Abstract][Full Text] [Related]
8. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
[TBL] [Abstract][Full Text] [Related]
9. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
Chen W; Xiao Z; Zhao Y; Huang L; Du G
Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
[TBL] [Abstract][Full Text] [Related]
13. MGMT immunoexpression in adamantinomatous craniopharyngiomas.
Zuhur SS; Müslüman AM; Tanık C; Karaman O; Oztürk FY; Ozderya A; Ozkayalar H; Aydın Y; Altuntaş Y
Pituitary; 2011 Dec; 14(4):323-7. PubMed ID: 21318329
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
16. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
17. Implications of MGMT methylation status in pituitary adenoma.
Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
[TBL] [Abstract][Full Text] [Related]
18. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
[TBL] [Abstract][Full Text] [Related]
19. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
